Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Naloxegol in Cancer Opioid-Induced Constipation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02745353
Recruitment Status : Recruiting
First Posted : April 20, 2016
Last Update Posted : March 1, 2017
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Eric Roeland, M.D., University of California, San Diego

Brief Summary:
The purpose of this study is to compare the effect of naloxegol versus the patient's usual care in treating opioid-induced constipation, as well as the effect on the patient's quality of life and how much pain is experienced. Also, the purpose of this study is to compare whether treatment with naloxegol versus usual care has any impact on the number of hospital or clinic visits or telephone calls to the patient's physician that are related to constipation, and to determine the patient's preference for continuing to receive naloxegol as treatment for opioid-induced constipation.

Condition or disease Intervention/treatment Phase
Constipation Drug: naloxegol Phase 2

Detailed Description:

Opioid-induced constipation (OIC) is a common symptom in patients with cancer-related pain and requires burdensome self-titration of laxatives for prophylaxis and treatment. Consequently, naloxegol may have an important role in this setting. Naloxegol has been evaluated in relieving OIC with cancer patients in a randomized, double blind, placebo-controlled trial over 4 weeks with a 12-week extension phase. However, accrual was challenging and the trial was closed early. Given the complexity of cancer and its treatment, a key first step is to determine if evaluating naloxegol versus standard of care is feasible in the management of OIC in this setting.

Subjects will receive naloxegol 25mg daily or usual care for a 2-week initial treatment period followed by 3-day washout period, then a 2-week crossover treatment period where subjects will receive naloxegol or usual care. Treatment assignment during the initial and crossover treatment periods will be dictated by the randomization arm. Subjects will also have the option to participate in a 12-week extension phase of naloxegol.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Single Center, Pilot Feasibility Study to Evaluate Naloxegol for Opioid-Induced Constipation in Cancer Patients
Study Start Date : May 2016
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation
Drug Information available for: Naloxegol

Arm Intervention/treatment
Active Comparator: A
Patients in Arm A will receive a single daily dose of 25mg naloxegol for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover treatment period in which the patient will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication.
Drug: naloxegol
Other Name: MOVANTIK

Active Comparator: B
Patients in Arm B will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover period in which the patient will receive a single daily dose of 25mg naloxegol.
Drug: naloxegol
Other Name: MOVANTIK




Primary Outcome Measures :
  1. feasibility [ Time Frame: 4 weeks ]
    completion of all study drugs



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults greater than or equal to 18 years old.
  • Eastern Cooperative Oncology Group (ECOG) less than or equal to 3.
  • Glomerular filtration rate (GFR) greater than or equal to 30 ml/min/1.73m2 by Modification of Diet in Renal Disease (MDRD).
  • Corrected serum calcium level less than or equal to 10.5 mg/dL.
  • Estimated life expectancy greater than or equal to 6 months.
  • Negative pregnancy test prior to initiating study treatment for females of childbearing potential.

Exclusion Criteria:

  • Patients receiving the following medications within 3 days of Study Day 1 and/or are planned to receive throughout the duration of the study period: opioid antagonist, mixed antagonist, a strong CYP3A4 and/or P-glycoprotein (P-gp) inhibitor, a moderate CYP3A4 and/or P-gp inhibitor, and/or a strong CYP3A4 inducer.
  • Concurrent total parenteral nutrition and/or use of metoclopramide.
  • Patients at high risk for bowel perforation.
  • Constipation that was not primarily caused by opioids in the investigator's medical opinion.
  • A condition that may have affected the permeability of the blood-brain barrier (e.g., known brain metastases, meningeal metastases, brain injury, multiple sclerosis, recent brain injury, uncontrolled epilepsy)
  • Patient has clinically active diverticular disease.
  • Past medical history of irritable bowel syndrome, signs of active gastrointestinal (GI) bleeding, acute surgical abdomen, bowel stents, indwelling peritoneal catheter, mechanical GI obstruction, fecal impaction, or fecal ostomy.
  • Patient has motility/neurologic disorders including autonomic failure (spinal cord lesions, tumor invasion of nerves) and/or poorly controlled endocrine/metabolic disorders (hypercalcemia, hypokalemia, diabetes, hypothyroidism), as determined by the investigator.
  • Uncontrolled cancer pain despite analgesic therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02745353


Contacts
Layout table for location contacts
Contact: Chelsea Hagmann chagmann@ucsd.edu

Locations
Layout table for location information
United States, California
UCSD Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
Sponsors and Collaborators
University of California, San Diego
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Eric Roeland, MD University of California, San Diego

Layout table for additonal information
Responsible Party: Eric Roeland, M.D., Assistant Clinical Professor, University of California, San Diego
ClinicalTrials.gov Identifier: NCT02745353     History of Changes
Other Study ID Numbers: 160121
First Posted: April 20, 2016    Key Record Dates
Last Update Posted: March 1, 2017
Last Verified: February 2017

Keywords provided by Eric Roeland, M.D., University of California, San Diego:
Cancer
Constipation
Opioid

Additional relevant MeSH terms:
Layout table for MeSH terms
Constipation
Signs and Symptoms, Digestive
Signs and Symptoms
Analgesics, Opioid
Naloxegol
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists